iSpecimen (ISPC) risk factors

78 risks, 1 new, 1 dropped, 5 reworded since the prior year. The company faces a Nasdaq delisting threat after its stock price fell below $1.00 for 30 consecutive business days. Net losses narrowed to $10,487,532 in 2025, but accumulated deficit grew to $82,350,149. Supply chain dependency shifted slightly and specimen quality compliance rates were updated for 2025.

78 risks. iSpecimen faces substantial going concern doubt due to ongoing net losses and an accumulated deficit of $71.86 million in 2024. The company is supply-constrained, highly dependent on transactional revenue from a few customers and suppliers, and suffers from internal controls weaknesses.